AngioDynamics Wins Humana Medicare Advantage Coverage for NanoKnife IRE

Humana updated its policy to apply LCD L40205 medical-necessity criteria to NanoKnife IRE for eligible intermediate-risk prostate cancer and certain liver tumors, effective Oct. 1, 2026.